U.S., Feb. 28 -- ClinicalTrials.gov registry received information related to the study (NCT06848699) titled 'A Phase Ib/II Clinical Study to Evaluate HLX43 in Combination with Serplulimab in Patients with Advanced/metastatic Solid Tumors' on Jan. 22.
Brief Summary: The study is being conducted to explore the reasonable dosage and evaluate the efficacy, safety and tolerability of HLX43 (Anti-PD-L1 ADC) in combination with Serplulimab (anti-PD-1 humanized monoclonal antibody injection) in patients with advanced/metastatic solid tumors
Study Start Date: Feb. 27
Study Type: INTERVENTIONAL
Condition:
Solid Tumor Cancer
Non Small Cell Lung Cancer
Intervention:
DRUG: HLX43 dose 1
HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a...